Combination strategies to maximize the benefits of cancer immunotherapy
S Zhu, T Zhang, L Zheng, H Liu, W Song, D Liu… - Journal of hematology & …, 2021 - Springer
Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy
(ACT) have revolutionized cancer treatment, especially in patients whose disease was …
(ACT) have revolutionized cancer treatment, especially in patients whose disease was …
Immunomodulation by targeted anticancer agents
At odds with conventional chemotherapeutics, targeted anticancer agents are designed to
inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite …
inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite …
Myeloid-derived suppressor cells in solid tumors
Myeloid-derived suppressor cells (MDSCs) are one of the main suppressive cell population
of the immune system. They play a pivotal role in the establishment of the tumor …
of the immune system. They play a pivotal role in the establishment of the tumor …
[HTML][HTML] Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity
MD Sharma, R Pacholczyk, H Shi, ZJ Berrong… - Immunity, 2021 - cell.com
Monocytic-lineage inflammatory Ly6c+ CD103+ dendritic cells (DCs) promote antitumor
immunity, but these DCs are infrequent in tumors, even upon chemotherapy. Here, we …
immunity, but these DCs are infrequent in tumors, even upon chemotherapy. Here, we …
Bruton's tyrosine kinase inhibitors (Btkis): review of Preclinical studies and evaluation of clinical trials
D Rozkiewicz, JM Hermanowicz, I Kwiatkowska… - Molecules, 2023 - mdpi.com
In the last few decades, there has been a growing interest in Bruton's tyrosine kinase (BTK)
and the compounds that target it. BTK is a downstream mediator of the B-cell receptor (BCR) …
and the compounds that target it. BTK is a downstream mediator of the B-cell receptor (BCR) …
Role of tumor-associated myeloid cells in breast cancer
YJ Cha, JS Koo - Cells, 2020 - mdpi.com
Stromal immune cells constitute the tumor microenvironment. These immune cell subsets
include myeloid cells, the so-called tumor-associated myeloid cells (TAMCs), which are of …
include myeloid cells, the so-called tumor-associated myeloid cells (TAMCs), which are of …
[HTML][HTML] Tumor microenvironment of human breast cancer, and feline mammary carcinoma as a potential study model
C Nascimento, F Ferreira - Biochimica Et Biophysica Acta (BBA)-Reviews …, 2021 - Elsevier
In recent years, the tumor microenvironment (TME) has been a research hotspot, as it is
composed of distinct cellular and non-cellular elements that may influence the diagnosis …
composed of distinct cellular and non-cellular elements that may influence the diagnosis …
The immune landscape of breast cancer: strategies for overcoming immunotherapy resistance
K Retecki, M Seweryn, A Graczyk-Jarzynka, M Bajor - Cancers, 2021 - mdpi.com
Simple Summary Immunotherapy is a rapidly advancing field in breast cancer treatment,
however, it encounters many obstacles that leave open gateways for breast cancer cells to …
however, it encounters many obstacles that leave open gateways for breast cancer cells to …
Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond
Y Zhao, J Du, X Shen - Frontiers in Immunology, 2023 - frontiersin.org
Myeloid-derived suppressor cells (MDSCs) are one of the major negative regulators in tumor
microenvironment (TME) due to their potent immunosuppressive capacity. MDSCs are the …
microenvironment (TME) due to their potent immunosuppressive capacity. MDSCs are the …
Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition
Over the past decade, immune checkpoint inhibitor (ICI) therapy has been established as
the standard of care for many types of cancer, but the strategies employed have continued to …
the standard of care for many types of cancer, but the strategies employed have continued to …